Tide turns for Taiwan
Emerging markets have been all the rage this year, but, unusually, the rising tide has not lifted all boats.
Emerging markets have been all the rage this year, but, unusually, the rising tide has not lifted all boats.
In Asia, the more popular markets (in South Korea, for example) have risen upwards of 40% already in 2005. However, over in Taiwan investors have had a tougher time of it: there, stocks have actually fallen 6% year to date.
But might things finally be on the turn? Analysts at Merrill Lynch think so, says George Hsu on Bloomberg.com. They have just started to recommend that investors buy in to the country in the wake of better-than-expected third-quarter GDP numbers and improving corporate prospects.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Taiwanese companies are working off their inventories, orders are rebounding and earnings downgrades are coming to an end, says Leslie Norton in Barron's, with the happy result that, according to Citigroup, average earnings will rise a nice 23% in 2006 (company earnings in Korea are only forecast to grow 14% over the same period).
A good way to gain exposure to Taiwan is via an exchange traded fund. Barclays Global Investors have recently launched the MSCI Taiwan iShare (www.ishares.net).
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
What the Employment Rights Bill means for your job
New workplace reforms are set to give employees new rights to benefits and flexible working
By Marc Shoffman Published
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published